A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Lead Sponsor

Eli Lilly and Company

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Have a body mass index (BMI) ≥27 kilogram/square meter (kg/m²)
•Have either
•* no T2D with an HbA1c \< 6.5% or
•* have T2D with an HbA1c ≤ 9.5% and treated with diet and exercise only or with stable doses of up to 3 oral antihyperglycemic medications, with or without basal insulin for at least 90 days before screening.
•Have been diagnosed with chronic kidney disease (CKD).

•Have a self-reported change in body weight \>5 kilogram (kg) (11 pounds) within 90 days before screening.
•Have used in 90 days before the screening any of the following antihyperglycemic class: Dipeptidyl Peptidase IV (DPP4) inhibitors, amylin analogs, glucagon-like peptide-RA (GLP-RA), gastric inhibitory polypeptide (GIP)/GIP-1 RA, and short acting or rapid acting insulins or U500 Insulin
•Have a prior or planned surgical treatment for obesity
•Have Type 1 Diabetes (T1D)
•Have acute or chronic hepatitis
•Have a history of malignant disease within 5 years before screening.